Compare TLYS & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLYS | ATOS |
|---|---|---|
| Founded | 1982 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 36.2M |
| IPO Year | 2011 | 2010 |
| Metric | TLYS | ATOS |
|---|---|---|
| Price | $5.05 | $4.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 2.2M | 69.1K |
| Earning Date | 03-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.34 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | $4.66 | N/A |
| Revenue Next Year | $1.74 | N/A |
| P/E Ratio | $17.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.53 |
| 52 Week High | $5.22 | $7.56 |
| Indicator | TLYS | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 90.15 | 51.86 |
| Support Level | $1.38 | $4.59 |
| Resistance Level | N/A | $5.12 |
| Average True Range (ATR) | 0.37 | 0.42 |
| MACD | 0.04 | -0.09 |
| Stochastic Oscillator | 90.03 | 24.00 |
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion, and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.